Regeneron Pharmaceuticals Inc. (REGN) Q1 2026 (USD): EPS 9.47 (exp. 8.80), Revenue 3.61bln (exp. 3.47bln)
Importance
Level 1
Sales Breakdown (USD)
- Dupizent 4.9bln, +33%
#UNITED STATES#USD#EUR#FRANCE#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#REGENERON PHARMACEUTICALS INC#REGN.US#SANOFI#SAN.FP#BANCO SANTANDER SA#FOREX#EQUITIES#METALS#EU SESSION#BIOTECHNOLOGY#PHARMACEUTICALS#DIVERSIFIED BANKS#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS (GROUP)#BANKS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BANKS (GROUP)#SAN#EURO STOXX 50#S&P 500 INDEX#CAC 40 INDEX#NASDAQ 100 INDEX#SANOFI SA#REGN#DXY#US EQUITIES